Two clocks. One drug. And a deadline that can’t be negotiated.
In pharma, timelines don’t just matter—they decide outcomes. Yet most conversations about “when generics hit” miss the real mechanism: it’s rarely one clock. It’s two.
A recent DrugPatent…

Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/

Small Molecules vs. Biologics: The “Same” Patent Fight—But a Completely Different Playbook for Generics vs. Biosimilars
Most people think the patent strategy for generics and biosimilars is a variation of the same theme: find the weak link, challenge t…

Biopharma’s next growth frontier isn’t a new molecule—it’s the tender.
When a drug approaches loss of exclusivity, the market doesn’t just “open.” It reorders. Prices compress, formularies tighten, procurement teams get more aggressive, and incumbent…

Pharma doesn’t just “discover” new drugs. It monetizes old ones.
There’s a quiet business model reshaping global drug spending: take a molecule that’s already been proven, already manufactured, already understood—and then repackage it as something new….

Biopharma is entering a new kind of “cliff”—not just the patent cliff, but the operational cliff that comes with it.
When a blockbuster’s exclusivity window ends, the market doesn’t simply shift from premium to generic. It shifts from certainty to chao…

One-shot: How to pick the right drug patent for maximum term-extension value
In pharma, time is money—and in patent strategy, time is often the only thing you can’t manufacture.
The industry has learned this the hard way: a “good” patent isn’t always a…

Drug development is a high-stakes chess match—except the board is made of patents, the pieces are formulations, and the rules change every time a claim is construed.
In the pharmaceutical space, “design around” is often discussed as a strategy. But in …

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion problem—and most teams are still treating it like a paperwork issue.
Patent term restoration (PTR) and patent term adjustment (PTA) sound like interchangeable regulatory footnotes. They’re not. Misread the clock, and you don’t…